Table of contents
In This Issue
p439 | doi:10.1038/nrd2077
Editorial: What's in a name?
p441 | doi:10.1038/nrd2078
News and Analysis
Industry sweats after patent verdict | PDF (812 KB)
p443 | doi:10.1038/nrd2071
First generic biologics finally approved | PDF (173 KB)
p445 | doi:10.1038/nrd2072
News in Brief
| PDF (298 KB)
p446 | doi:10.1038/nrd2073
Patent watch
Patent trolls hit by injunction ruling | PDF (108 KB)
p448 | doi:10.1038/nrd2074
An Audience With
Melinda Moree | PDF (145 KB)
p450 | doi:10.1038/nrd2079
From the analyst's couch
The 'not invented here' myth | PDF (198 KB)
p451 | doi:10.1038/nrd2063
Fresh from the Pipeline
Ranolazine | PDF (142 KB)
p453 | doi:10.1038/nrd2069
Research Highlights
Personalized medicine: Predicting predisposition | PDF (377 KB)
p455 | doi:10.1038/nrd2064
G-Protein-coupled receptors: Targeting the hotspot of G-protein interactions | PDF (82 KB)
p456 | doi:10.1038/nrd2065
Cancer: Blocking LOX prevents cancer spread | PDF (67 KB)
p456 | doi:10.1038/nrd2066
Ion channels: Fast track to ion-channel modulators | PDF (118 KB)
p458 | doi:10.1038/nrd2067
In brief
Cardiovascular disease | Pharmacogenetics | Drug delivery | Stroke | PDF (125 KB)
p458 | doi:10.1038/nrd2068
Anti-Inflammatory Drugs: New clues in the COX2 mystery | PDF (120 KB)
p4571 | doi:10.1038/nrd2061
Perspectives
Opinion
Impact of genetic diagnostics on drug development strategy
Ryan P. Million
p459 | doi:10.1038/nrd2034
Advancement in personalized medicine depends on concurrent innovation in diagnostics and therapeutics. To remain competitive, drug discovery companies must embrace the powerful combination of genetic information in drug-responders and diagnostics that identify patient sub-groups.
Article series: Biomarkers
Outlook
Diagnostics and biomarker development: priming the pipeline
Kathryn A. Phillips, Stephanie Van Bebber & Amalia M. Issa
p463 | doi:10.1038/nrd2033
The reasons for the shortage of new drugs coming through the pipeline are the subject of much debate, and the pipeline for diagnostics is one factor that will become increasing relevant to this problem as the co-development of drugs and diagnostics becomes more common. Phillips and colleagues examine the characteristics of the pipeline for diagnostics and biomarkers, and consider what steps could be taken to solve the problems identified.
Reviews
Therapeutic potential of Toll-like receptor 9 activation
Arthur M. Krieg
p471 | doi:10.1038/nrd2059
The discovery of Toll-like receptors (TLRs) offers the possibility to treat diseases by stimulating immune functions in a targeted manner. Krieg reviews the potential of synthetic DNAs that activate TLR9 and are in clinical development in cancer, infectious disease and asthma/allergy.
Article series: Biomarkers
Biomarkers: Application of intravascular ultrasound in anti-atherosclerotic drug development
Stephen J. Nicholls, Ilke Sipahi, Paul Schoenhagen, Tim Crowe, E. Murat Tuzcu & Steven E. Nissen
p485 | doi:10.1038/nrd2040
The challenge of predicting potential efficacy of anti-atherosclerotic drugs before the completion of long-term trials with endpoints such as mortality has stimulated efforts to develop intermediate measures of efficacy. Nissen and colleagues describe how intravascular ultrasound can be applied to the serial assessment of atheroma burden in response to treatment, which has resulted in its emergence as a key technology in the evaluation and approval of novel drugs.
Therapeutic potential of resveratrol: the in vivo evidence
Joseph A. Baur & David A. Sinclair
p493 | doi:10.1038/nrd2060
Resveratrol is the constituent of red wine that has an array of protective effects in vitro and in animal models. Baur and Sinclair provide a comprehensive review of the in vivo evidence that suggests resveratrol has therapeutic potential in humans.
Protein therapeutics: new applications for pharmacogenetics
Cecile Krejsa, Mark Rogge & Wolfgang Sadee
p507 | doi:10.1038/nrd2039
Target-oriented pharmacogenetic studies offer a unique opportunity to understand variations in response to highly selective protein therapeutics. Krejsa and colleagues review recent pharmacogenetic investigations of protein drugs, and present a case for initiating such studies during early clinical development.
